利用大肠埃希菌生产N-糖基化重组蛋白研究进展

Research Progress of Producing N-glycosylated Recombinant Protein via Escherichia coli

利用大肠埃希菌生产N-糖基化重组蛋白已经成为糖工程研究热点之一。由于真核生物系统生产N-糖基化蛋白普遍存在培养周期长、过程复杂及所需成本高的问题,因此遗传背景清晰、培养周期短、所需成本低的大肠埃希菌作为生产蛋白质药物的工具越来越受到关注,在生产治疗性N-糖基化蛋白方面具有很大的潜力。本文介绍了大肠埃希菌生产N-糖基化重组蛋白的机制,综述了利用大肠埃希菌生产N-糖基化重组蛋白及糖疫苗的研究进展,对值得进一步深入研究的问题进行总结和展望,以期为后续构建稳定高效的大肠埃希菌生产N-糖基化重组蛋白系统提供参考。

The production of N-glycosylated recombinant proteins using Escherichia coli has become one of the hot studies in glycoengineering. Escherichia coli is increasingly concerned as a popular host for producing protein drugs, and has great potentials for the production of therapeutic N-glycoproteins as it′s clear genetic background, short culture cycles and low costs, contrasting to the long culture cycle, complex process and high cost of N-glycosylated protein produced by eukaryotic systems. In this paper, we introduced the mechanism of producing N-glycosylated recombinant proteins with Escherichia coli, and reviewed the research progress of N-glycosylated recombinant proteins and glycoconjugate vaccine via Escherichia coli, finally summarized the worthy studies and research directions in future, expecting to serve as a reference for the subsequent construction of a stable and efficient system for N-glycosylated recombinant protein via Escherichia coli.